Skip to main content
padlock icon - secure page this page is secure

Nanocochleates as the Potential Delivery Systems for Oral Antitumor of Hydroxycamptothecin

Buy Article:

$106.65 + tax (Refund Policy)

It remains a major challenge to improve the oral antitumor efficacy of hydroxycamptothecin (HCPT). The aim of this study was to develop the oral HCPT formulation via nanocochleates technology. After HCPT was incorporated into calcium ions-induced nanocochleates, its oral bioavailability significantly enhanced, up to a 2.3-fold. Most importantly, in vivo antitumor effect of HCPT-loaded nanocochleates could be achieved upon oral administration to hepatoma-bearing BALB/c-nude mice, showing the remarkable inhibition of tumor growth as compared to normal saline, HCPT suspensions and HCPT-loaded liposomes. Caco-2 cells, as an in vitro model, were conducted to investigate the absorption mechanisms of intestinal tract. Caco-2 transport studies indicated that HCPT-loaded nanocochleates were uptake via clathrin- and caveolin-mediated endocytosis. Furthermore, ZO-1, F-actin and claudin-4, known as three cellular tight junction proteins, were obvious down-regulation, which suggested that HCPT-loaded nanocochleates could open cellular tight junctions and paracellular route. In conclusion, nanocochleates served as a promising vehicle to facilitate the oral delivery of HCPT.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: ANTITUMOR EFFICACY; HYDROXYCAMPTOTHECIN; MICE; NANOCOCHLEATES; ORAL DELIVERY

Document Type: Research Article

Publication date: July 1, 2018

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more